Sector perspective
Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.
Product concentration, research investment, utilization, reimbursement and cash generation.
Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration.
Company selection is editorial, not GICS. These annual snapshots have different fiscal year ends and are not a sector index. Each data note shows the full eligible sample and source filings.
Pharmaceutical Preparations
ABTPharmaceutical Preparations
AMGNBiological Products, (No Diagnostic Substances)
AZNPharmaceutical Preparations
BMYPharmaceutical Preparations
GILDBiological Products, (No Diagnostic Substances)
HCAServices-General Medical & Surgical Hospitals, NEC
ISRGOrthopedic, Prosthetic & Surgical Appliances & Supplies
JNJPharmaceutical Preparations
LLYPharmaceutical Preparations
MDTElectromedical & Electrotherapeutic Apparatus
MRKPharmaceutical Preparations
NVSPharmaceutical Preparations
PFEPharmaceutical Preparations
SYKSurgical & Medical Instruments & Apparatus
VRTXPharmaceutical Preparations
Across 12 eligible healthcare companies, the equal-weight median capital expenditure as a share of revenue was 3.96% for the prior selected annual periods.
Across 12 eligible healthcare companies, the equal-weight median capital expenditure as a share of revenue was 4.55% for the latest selected annual periods.
Across 15 eligible healthcare companies, the equal-weight median operating cash-flow margin was 21.94% for the prior selected annual periods.
Across 15 eligible healthcare companies, the equal-weight median operating cash-flow margin was 25.80% for the latest selected annual periods.
Across 14 eligible healthcare companies, the equal-weight median equity as a share of assets was 39.38% for the prior selected annual periods.
Across 14 eligible healthcare companies, the equal-weight median equity as a share of assets was 40.00% for the latest selected annual periods.
Across 9 eligible healthcare companies, the equal-weight median liabilities as a share of assets was 56.84% for the prior selected annual periods.
Across 9 eligible healthcare companies, the equal-weight median liabilities as a share of assets was 57.29% for the latest selected annual periods.
Across 15 eligible healthcare companies, the equal-weight median net margin was 13.02% for the prior selected annual periods.
Across 15 eligible healthcare companies, the equal-weight median net margin was 17.42% for the latest selected annual periods.
Across 9 eligible healthcare companies, the equal-weight median operating margin was 16.33% for the prior selected annual periods.
Across 9 eligible healthcare companies, the equal-weight median operating margin was 24.65% for the latest selected annual periods.
Across 15 eligible healthcare companies, the equal-weight median revenue growth was 8.67% for the prior selected annual periods.
Across 15 eligible healthcare companies, the equal-weight median revenue growth was 8.43% for the latest selected annual periods.
A two-period review of ABBV revenue, profitability and cash conversion; reported revenue growth was 8.57%.
Annual revenue of USD 61.160 billion and net income of USD 4.226 billion for the period ended 2025-12-31.
Annual revenue of USD 44.328 billion and net income of USD 6.524 billion for the period ended 2025-12-31.
A two-period review of AMGN revenue, profitability and cash conversion; reported revenue growth was 9.95%.
Annual revenue of USD 36.751 billion and net income of USD 7.711 billion for the period ended 2025-12-31.
A two-period review of AZN revenue, profitability and cash conversion; reported revenue growth was 8.63%.